Business
Propanc Biopharma Peer Reviewed Scientific Article Reaches 3,000 Reads
Reader interest above 93% of published research articles over the past year MELBOURNE, Australia--(BUSINESS WIRE)-- Propanc Biopharma, Inc. (OTC Pink: PPCB)
About this update from Propanc Biopharma, Inc.
[{"type":"text","content":"\nReader interest above 93% of published research articles over the past year\n\n\n MELBOURNE, Australia--(BUSINESS WIRE)--\nPropanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that a peer reviewed scientific article published by the Company and its research partners reached 3,000 reads on July 6, 2023, according to ResearchGate. The achievement demonstrates reader interest above 93% of published research articles over the past year, “therefore, this shows exceptional interest in our work and bodes well for our future, both clinical and academic,” according to Dr Julian Kenyon, MD, MB, ChB, Propanc’s Chief Scientific Officer.\n\n\nThe article, published in the peer reviewed journal, Scientific Reports, is entitled, “A formulation of pancreatic proenzymes provides potent anti-tumor efficacy: A pilot study focused on pancreatic and ovarian cancer.” From the publishers of Nature, it is an online, open access journal, which publishes primary research from all areas of the natural and clinical sciences. Published data from the Company's R&D program were conducted with Universities of Jaén and Granada and University Hospital, Spain, vivoPharm Pty Ltd, Australia, and the Dove Clinic for Integrated Medicine, UK. Highlights include the anti-angiogenic (anti blood vessel formation) effects of the Company’s lead product candidate, PRP, by using fibrous capsule formation assays, as well as cell invasion and wound healing assays, along with analysis of epithelial to mesenchymal transition (EMT) markers performed on human cancer cells treated with PRP. The EMT is a mechanism by which cancerous cells become motile and invasive, as well as immortal, thus seeding new tumors. It is fundamental to how cancerous cells become “stem cell” like, causing tumors to spread. Spreading cancer, called, “metastatic cancer,” is the main cause of patient death for sufferers.\n\n\nOf note in the publication is the evaluation of clinical efficacy of a suppository formulation of pancreatic proenzymes in the context of a UK Pharmaceutical Specials Scheme, led by Dr Kenyon, where 19 from 46 patients (41.3%) with late-stage cancers, most suffering from metastases, had a survival time significantly longer than ...